Project Grant R03NS142535
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $131,360 to the University of New Haven, Incorporated, effective September 1, 2025, through August 31, 2029, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). This research initiative focuses on characterizing glioblastoma stem cell (GSC)-associated long noncoding RNA (lncRNA) GIHCG as a potential therapeutic target...
- Federal Project Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $638,697 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective July 15, 2025, through June 30, 2030. The award supports research investigating the role of SMARCA5, an ISWI (Imitation Switch/Chromatin Remodeling)...
- Federal Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $442,750 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 1, 2025 through July 31, 2027. The award funds research focused on inducing and imaging extrachromosomal DNA (ecDNA) in human glioblastoma. The project...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, will fund research to target cell-scaffolding proteins that contribute to radioresistance in glioblastoma, an aggressive brain cancer. The $448,250 award to The Research Foundation For The State University Of New York, operating as Upstate Medical Center, will support a 2-year...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research on a novel signaling axis involving the protein connexin 43 (CX43) and its role in regulating cancer stem cells in glioblastoma, the most common and deadly form of brain cancer. The $161,000 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve...
- The University of Texas MD Anderson Cancer Center received a $460,940 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 1, 2025, through May 31, 2027. This award supports investigator-initiated research examining how glioma-associated germline risk alleles (single nucleotide polymorphisms or SNPs) impact neurodevelopmental...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $595,047 to the University of California, Los Angeles (UCLA) on August 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to investigate non-apoptotic cell death mechanisms in glioblastoma (GBM). This five-year research project will deliver fundamental scientific research and mechanistic studies examining a novel form of...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $452,375 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on August 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The two-year project, concluding July 31, 2027, will investigate nuclear mechano-transduction (NMT) mechanisms in glioblastoma, the most common malignant...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Leland Stanford Junior University a Project Grant of $209,177 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective February 1, 2026, with a completion date of January 31, 2031. The research project, "Targeting the MAP4K4 Pathway to Inhibit Pediatric High-Grade Glioma Invasion," focuses on identifying and...
DECIPHERING THE ROLE OF THE NOVEL LONG NON-CODING RNA LINC01896 IN GLIOBLASTOMA MULTIFORME - PROJECT SUMMARY GLIOBLASTOMA MULTIFORME (GBM) IS THE MOST AGGRESSIVE AND COMMON PRIMARY BRAIN TUMOR, POSING SIGNIFICANT CLINICAL CHALLENGES DESPITE MULTIMODAL TREATMENTS LIKE SURGICAL RESECTION, CHEMOTHERAPY, AND RADIATION. THE PROGNOSIS FOR GBM PATIENTS REMAINS POOR, PRIMARILY DUE TO ITS INEVITABLE RECURRENCE AND RESISTANCE TO STANDARD THERAPIES. THEREFORE, IDENTIFYING NOVEL MOLECULAR DRIVERS OF GBM PROGRESSION IS ESSENTIAL FOR DEVELOPING MORE EFFECTIVE TREATMENTS. OVER THE PAST DECADE, THE ISOLATION OF GLIOBLASTOMA STEM CELLS (GSCS) HAS PROVIDED CRUCIAL INSIGHTS INTO TUMOR INITIATION, MAINTENANCE, AND RECURRENCE, POSITIONING THEM AS A MAJOR THERAPEUTIC TARGET. CONCURRENTLY, ADVANCES IN GENOMIC RESEARCH HAVE REVEALED A VAST LANDSCAPE OF LONG NONCODING RNAS (LNCRNAS), OFFERING NEW OPPORTUNITIES TO INFLUENCE GENE REGULATION AND CANCER BIOLOGY. ALTHOUGH TENS OF THOUSANDS OF LNCRNAS HAVE BEEN DISCOVERED, ONLY A SMALL FRACTION HAVE BEEN FUNCTIONALLY CHARACTERIZED. EMERGING EVIDENCE SUGGESTS THAT LNCRNAS EXHIBIT CELL-TYPE-SPECIFIC EXPRESSION, DISTINCT SUBCELLULAR LOCALIZATION, AND CRITICAL ROLES IN KEY ONCOGENIC PROCESSES, INCLUDING PROLIFERATION, INVASION, AND THERAPY RESISTANCE. THESE PROPERTIES HIGHLIGHT THEIR POTENTIAL AS BOTH BIOMARKERS AND THERAPEUTIC TARGETS IN GBM. IN THIS STUDY, WE PROPOSE TO CHARACTERIZE THE NUCLEAR-RETAINED ONCOGENIC LNCRNA, LINC01896, WHICH IS SIGNIFICANTLY UPREGULATED IN GSCS. OUR PRELIMINARY DATA SHOW THAT DEPLETION OF LINC01896 IMPAIRS GSC PROLIFERATION AND STEMNESS, EMPHASIZING ITS CRITICAL ROLE IN GSC MAINTENANCE. FURTHERMORE, HIGHER LEVEL OF LINC01896 CORRELATES WITH POOR OVERALL AND DISEASE-FREE SURVIVAL IN GBM PATIENTS, SUGGESTING ITS POTENTIAL AS BOTH A PROGNOSTIC BIOMARKER AND A THERAPEUTIC TARGET. WE WILL INVESTIGATE HOW LINC01896 REGULATES GLOBAL GENE EXPRESSION IN GSCS AND IDENTIFY THE MOLECULAR PATHWAYS DRIVING GSC PROLIFERATION AND STEMNESS. ADDITIONALLY, WE WILL EXAMINE THE FUNCTIONAL IMPACT OF LINC01896 KNOCKDOWN IN GSCS USING ANTISENSE OLIGONUCLEOTIDES (ASOS) AND EVALUATE THESE EFFECTS IN PRECLINICAL 3D CEREBRAL ORGANOID MODEL, WHICH MIMIC THE HUMAN BRAIN'S CELLULAR COMPLEXITY AND TUMOR MICROENVIRONMENT. FURTHERMORE, WE WILL MAP THE TRANSCRIPTOMIC LANDSCAPE OF GSCS AND THEIR TUMOR MICROENVIRONMENT USING SINGLE-CELL RNA SEQUENCING. TOGETHER, THESE STUDIES AIM TO ELUCIDATE THE REGULATORY ROLE OF LINC01896 IN GSC BIOLOGY AND PAVE THE WAY FOR THE DEVELOPMENT OF INNOVATIVE LNCRNA-BASED THERAPEUTIC STRATEGIES FOR GBM PATIENTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $69.6k | 3/19/26 |